US 11,932,871 B2
Methods of culturing t cells and uses of same
Benjamin Geiger, Rehovot (IL); Nir Friedman, Rehovot (IL); Shimrit Lieber, Rehovot (IL); Zelig Eshhar, Rehovot (IL); Tova Waks, Rehovot (IL); and Anat Globerson Levin, Rehovot (IL)
Assigned to YEDA RESEARCH AND DEVELOPMENT CO. LTD., Rehovot (IL); and THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER, Tel-Aviv (IL)
Appl. No. 16/490,568
Filed by Yeda Research and Development Co. Ltd., Rehovot (IL); and The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center, Tel-Aviv (IL)
PCT Filed Mar. 2, 2018, PCT No. PCT/IL2018/050236
§ 371(c)(1), (2) Date Sep. 2, 2019,
PCT Pub. No. WO2018/158775, PCT Pub. Date Sep. 7, 2018.
Claims priority of application No. 250916 (IL), filed on Mar. 2, 2017.
Prior Publication US 2020/0071669 A1, Mar. 5, 2020
Int. Cl. C12N 5/0783 (2010.01); A61K 35/17 (2015.01)
CPC C12N 5/0636 (2013.01) [A61K 35/17 (2013.01); C12N 2501/21 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/515 (2013.01); C12N 2501/58 (2013.01); C12N 2502/1121 (2013.01); C12N 2510/00 (2013.01)] 10 Claims
 
1. A method of culturing T cells, the method comprising culturing T cells in a culture vessel in the presence of a T cell stimulator, an exogenous CCL21 and an exogenous ICAM1, thereby culturing the T cells, wherein each of said CCL21 and ICAM1 are immobilized to a solid support, wherein said T cell stimulator is an antigen-specific stimulator comprising a dendritic cell loaded with an antigen, wherein said immobilized CCL21 and ICAM1 are attached to said culture vessel, and wherein said T cells comprise engineered T cells transduced with a nucleic acid encoding a T cell receptor (TCR) or a chimeric antigen receptor (CAR).